What is ADXS stock price today?

ADXS (Ayala Pharmaceuticals Inc) stock is trading at $0.25 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is ADXS stock going up or down today?

ADXS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy ADXS stock now?

The decision to buy ADXS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is ADXS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for ADXS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is ADXS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if ADXS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is ADXS's P/E ratio?

P/E ratio data for ADXS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is ADXS's market cap?

ADXS (Ayala Pharmaceuticals Inc) has a market capitalization of $0.00 billion, making it a small-cap stock.

What is ADXS's price to book ratio?

Price-to-book ratio for ADXS is available on our dashboard along with other valuation metrics.

Does ADXS pay dividends?

ADXS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is ADXS's dividend yield?

ADXS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is ADXS stock a good long-term investment?

ADXS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is ADXS's revenue growth rate?

Revenue growth data for ADXS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for ADXS are available on our dashboard with complete income statement analysis.

What are the risks of investing in ADXS?

Key risks for ADXS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does ADXS compare to its competitors?

Compare ADXS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize ADXS's performance and positioning.

What is ADXS's stock price target for 2026?

Our AI model provides price targets for ADXS based on fundamental analysis: Bull case $0.33 (+30%), Base case $0.29 (+15%), Bear case $0.23 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about ADXS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for ADXS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is ADXS's next earnings report?

ADXS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

ADXS - Ayala Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$0.25

$-0.21 (-45.41%)

About Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Key Statistics

Market Cap

$1.71M

EPS

$-7.99

Employees

How ADXS Compares to Peers

ADXS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
ADXS(This stock)	$1.71M	N/A	0%	0.0%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Ayala Pharmaceuticals Inc Company Information

Headquarters: New Jersey; U.S.A
Website: www.ayalapharma.com
Sector: Health Care
Industry: Biotechnology

Data Updated: January 21, 2026 at 2:31 AM EST

Ready to invest in ADXS?

Commission-free trading available. Affiliate links.

ADXS Lician Score

10% confidence

5.0/10

Neutral

ADXS has a Lician Score of 5/10 (Average). Areas of concern: Growth.

value

5.0

growth

3.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates ADXSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

ADXS Financial Snowflake

5-axis analysis across key investment dimensions

4.6/10

Neutral

5.0

Value

Valuation vs. sector peers

3.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for ADXS

Dashboard

Enter a ticker to analyze